Imipenem Anhydrous

Summary

Imipenem Anhydrous (CHEMBL148) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 47
• Chemistry: 299.35 Da · C12H17N3O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL148
Name	Imipenem Anhydrous
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	104838
ChEBI	CHEBI:190509
Molecular formula	C12H17N3O4S
Molecular weight	299.35
InChIKey	ZSKVGTPCRGIANV-ZXFLCMHBSA-N

SMILES: C[C@H]([C@@H]1[C@H]2CC(=C(N2C1=O)C(=O)O)SCCN=CN)O

IUPAC name: (5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

ChEBI definition: Zwitterionic form of imipenem having an anionic carboxy group and a protonated methaneimidamido group; major species at pH 7.3.

Also known as: Imipenem (anhydrous), Imipenem anhydrous, Imipenem, Ureido trinem analogue, imipenem, Imipenam, imipenam, Imipenum, imepenem, SID90341794, SID144204240, N-formimidoylthienamycin

Parent form; salt/anhydrous children: CHEMBL43708

Patent coverage: 609 distinct patent families (1,386 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 1,269 (92%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 47.

Phase distribution

Phase	Trials
PHASE4	17
PHASE2	10
PHASE3	7
Not specified	7
PHASE1	4
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00871104	PHASE4	COMPLETED	Fosfomycin Plus Imipenem for Treatment of Infective Endocarditis
NCT01356472	PHASE4	UNKNOWN	Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Ventilator-associated Pneumonia
NCT01379157	PHASE4	COMPLETED	Pharmacodynamics Study of Imipenem in Patients With Ventilator Associated Pneumonia
NCT01489124	PHASE4	COMPLETED	The Population Pharmacokinetics of Imipenem in Patients With Ventilator-associated Pneumonia
NCT01659866	PHASE4	COMPLETED	Antibiotic Prophylaxis for Transrectal Prostate Biopsy
NCT01721408	PHASE4	COMPLETED	A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection
NCT01820026	PHASE4	UNKNOWN	Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis
NCT02213783	PHASE4	COMPLETED	Comparison of the Pharmacodynamics of Imipenem in Patients With Febrile Neutropenia
NCT02474706	PHASE4	TERMINATED	Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli
NCT02616354	PHASE4	UNKNOWN	Preliminary Research On Two-step Dosing Of Imipenem/Cilastatin
NCT02683603	PHASE4	COMPLETED	Effect of Aerosolised Colistin in Ventilator Associated Pneumonia
NCT02897206	PHASE4	COMPLETED	Imipenem Prophylaxis in Patients With Acute Pancreatitis
NCT03012360	PHASE4	TERMINATED	Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis
NCT03776305	PHASE4	UNKNOWN	Imipenem in Critically Ill Patients
NCT04785924	PHASE4	WITHDRAWN	Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections
NCT05146154	PHASE4	WITHDRAWN	Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients
NCT05561764	PHASE4	TERMINATED	Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis
NCT04310930	PHASE2/PHASE3	RECRUITING	Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
NCT06569056	PHASE3	RECRUITING	A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
NCT00080496	PHASE3	COMPLETED	Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia
NCT02452047	PHASE3	COMPLETED	Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)
NCT02493764	PHASE3	COMPLETED	Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)
NCT03733340	PHASE2/PHASE3	UNKNOWN	Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT
NCT03894046	PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
NCT05204563	PHASE3	COMPLETED	Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)
NCT05887908	PHASE3	COMPLETED	Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis
NCT07485010	PHASE2	NOT_YET_RECRUITING	Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
NCT07524920	PHASE2	NOT_YET_RECRUITING	Comparing Efficacy and Safety of (Meropenem + Colistin) Versus (Imipenem/Cilastatin + Tigecycline) on Eradication of Multi-Drug Resistance Bacteria
NCT00515034	PHASE2	COMPLETED	A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia
NCT00690378	PHASE2	COMPLETED	Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections
NCT00707239	PHASE2	TERMINATED	Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia
NCT01505634	PHASE2	COMPLETED	Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)
NCT01506271	PHASE2	COMPLETED	Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)
NCT02321800	PHASE2	COMPLETED	A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections
NCT04983901	PHASE2	COMPLETED	PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN
NCT06144060	PHASE2	UNKNOWN	A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis
NCT01275170	PHASE1	COMPLETED	A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)
NCT02971423	PHASE1	COMPLETED	Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects
NCT03177720	PHASE1	COMPLETED	Evaluation of Innovative Tools in Development of Antibiotics
NCT04801043	PHASE1	COMPLETED	To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).